32 -10 (84) 2025 - Tashkenbaeva N.F. - CONTEMPORARY APPROACHES TO CARDIOMETABOLIC THERAPY: AN INTEGRATED ANALYSIS OF SGLT2 INHIBITORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS

CONTEMPORARY APPROACHES TO CARDIOMETABOLIC THERAPY: AN INTEGRATED ANALYSIS OF SGLT2 INHIBITORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS

Tashkenbaeva N.F. - Republican Specialized Scientific and Practical Medical Center of Cardiology Uzbekistan

Resume

The contemporary strategy for managing patients with chronic heart failure (CHF) and chronic kidney disease (CKD) within the framework of cardiometabolic syndemia requires agents that target multiple key pathophysiological mechanisms simultaneously. Among the most promising pharmacologic classes are sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) and mineralocorticoid receptor antagonists (MRAs). This review presents robust clinical evidence from multicenter trials supporting their efficacy and discusses the perspectives for their combined application in clinical practice.

Keywords: SGLT2, finerenone, chronic heart failure, chronic kidney disease, combination therapy, cardiometabolic syndemia.

First page

172

Last page

176

For citation:Tashkenbaeva N.F. - CONTEMPORARY APPROACHES TO CARDIOMETABOLIC THERAPY: AN INTEGRATED ANALYSIS OF SGLT2 INHIBITORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS //New Day in Medicine 10(84)2025 172-176 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

1. Zannad F, Ferreira JP, Pocock SJ, et al. Empagliflozin in patients with heart failure and preserved ejection fraction. // N Engl J Med. 2021;385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038
2. Wheeler DC, Stefánsson BV, Batiushin M, et al. Dapagliflozin and prevention of adverse outcomes in chronic kidney disease. // N Engl J Med. 2020;383:1436–1446. https://doi.org/10.1056/NEJMoa2024816
3. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. // N Engl J Med. 2020;383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845
4. Filippatos G, Anker SD, Böhm M, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. // J Am Coll Cardiol. 2021;77(6):761–771. https://doi.org/10.1016/j.jacc.2020.11.048
5. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. // J Am Coll Cardiol. 2021;78(1):101–110. https://doi.org/10.1016/j.jacc.2021.04.002
6. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. // N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303
7. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. // N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744
8. Verma S, McMurray JJV, Cherney DZI. The role of SGLT2 inhibitors in modifying cardiac structure and function in heart failure. // Circulation. 2021;143(13):1336–1350. https://doi.org/10.1161/CIRCULATIONAHA.120.050123
9. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. // N Engl J Med. 2020;383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816
10. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis. // Lancet. 2019;393(10166):31–39. https://doi.org/10.1016/S0140-6736(18)32590-X

    file

    download